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Introduction: Lung cancer is the leading cause of cancer-related
deaths worldwide. New therapies targeting the epidermal growth
factor receptor (EGFR) tyrosine kinase are promising and show high
response rates in the subset of patients with activating mutations in
EGFR. The frequency of these mutations is largely unknown in
unselected Caucasian patients.
Methods: Mutation analysis of EGFR exons 18–21 was performed
on 240 lung cancer samples using the TheraScreen EGFR mutation
kit and denaturing high-performance liquid chromatography in ad-
dition to sequencing.
Results: In a cohort of 240 Norwegian lung cancer patients selected
for surgery, we identified 18 tumors with EGFR-activating muta-
tions (7.5%, 14 women and 4 men), of which 14 were adenocarci-
nomas, 2 squamous cell carcinomas, and 2 bronchoalveolar carci-
nomas. Five of the mutations were found in patients with more than
20 pack-years of smoking history.
Conclusion: The frequency of EGFR mutations is lower in our
cohort than among Asian lung cancer patients and present in both
men and women and smokers and never-smokers. However, the
frequency is significantly higher among women and never-smokers
and among patients with adenocarcinomas.
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Lung cancer accounts for approximately one-third of allcancer deaths worldwide. Non-small cell lung carcinoma
(NSCLC) can be categorized into several subtypes deter-
mined by specific molecular events, which may be mirrored
by the etiology. Analyses show that NSCLC among smokers
and never-smokers have different molecular characteristics.
One pivotal molecular event in subsets of NSCLC is
dysregulation of epidermal growth factor receptor (EGFR).
During the past years, several agents that target the EGFR
have been developed. Early studies identified the presence of
activating mutations in the kinase domain of the EGFR gene
as a marker of response,1–3 and the predictive value has
recently also been shown in clinical randomized studies.4
EGFR mutations have been found more frequently among
Asian, nonsmoking, female patients and are also present in
Caucasians.5 In a Spanish lung cancer cohort, approximately
16% of patients were found to have EGFR mutations, but
most of these patients were never-smokers.5,6 Little is known
about the exact frequency of EGFR mutations in Northern
European patients with lung cancer. In this study, we report
the frequency of EGFR mutations in exons 18–21 by both
quantitative-polymerase chain reaction (PCR) and sequenc-
ing in a Norwegian lung cancer patient cohort.
MATERIALS AND METHODS
Material
Tumor tissue was obtained from 240 operable lung
cancer patients admitted to Oslo University Hospital-Rik-
shospitalet during the period 2006–2010. Tissue was taken
from the excised tumors, snap frozen in liquid nitrogen in the
operation room, and stored at 80°C until DNA isolation.
The tumor cell content in the specimens was found to be more
than 70% in most samples. DNA was isolated from the
biopsies using chloroform/phenol extraction followed by eth-
anol precipitation using the Applied Biosystems (Foster City,
CA) 340A Nucleic Acid Extractor according to standard
protocol.
The project was approved by the institutional review
board and regional ethics committee, and written consent was
obtained from each participant.
Mutation Analyses
Mutation analysis of EGFR exons 18–21 was per-
formed on all samples using the TheraScreen EGFR mutation
kit (DxS, Manchester, UK). The assay is designed to detect
28 specific mutations in the EGFR gene by real-time PCR.
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It enables the detection of 19 distinguished deletions in
exon 19, L858R, L861Q, G719X, S768I, and three inser-
tions in exon 20. Assays were carried out according to the
manufacturer’s protocol and using the Roche LightCycler
480 real-time PCR system. Data analyses were performed
using the LightCycler Adapt software (LightCycler 480
Software, v1.5).
We additionally analyzed 107 of the samples by denatur-
ing high-performance liquid chromatography (dHPLC) followed
by sequencing. After amplification, DNA heteroduplexes were
detected on a WAVE 3500HT instrument (Transgenomic, Glas-
gow, UK) according to manufacturer’s standard procedure.
Samples displaying aberrant dHPLC chromatograms were se-
quenced using the BigDye Terminator v3.1 Cycle Sequenc-
ing Kit (Applied Biosystems, Carlsbad, CA). Capillary elec-
trophoresis was performed on the 3130l Genetic Analyzer
(Applied Biosystems). Mutation Surveyor (v3.30) and Se-
quence Scanner (v1.0, Applied Biosystems) were used for
sequence analysis.
Immunohistochemistry
Paraffin-embedded tissue was pretreated with Protei-
nase-K (DAKO) for antigene retrival. The following staining
procedure was performed according to the standardized pro-
tocol EnVision FLEX, Mouse, High pH (Dako Autostainer/
Autostainer Plus).
Statistical Analyses
Statistical analyses were performed using SPSS 16.
Relapse-free survival was defined as time between surgery
and relapse or death due to lung cancer. The Kaplan-Meier
method7 and the log-rank test were used to estimate and
compare survival rates. Statistical significance was defined as
p  0.05.
RESULTS
Patient Characteristics
Two hundred forty patients diagnosed with operable
lung cancer were included in this study. This is 53% of the
total number of lung cancer patients operated at our hospital
during this period of time and selected based on practicalities
(study nurse resources). The characteristics according to
gender, stage (TNM-7), histology, and smoking status is
presented in Table 1. Median age was 64 and 66 years for
female and male patients, respectively. One hundred forty-
one patients (54%) were diagnosed with adenocarcinoma and
63 (26%) with squamous cell carcinoma (Table 1). Fifteen
patients (6.2%) were never-smokers while 83 (34%) were
previous smokers, defined as having stopped smoking at least
1 year before surgery.
Adjuvant chemotherapy was offered patients based on
their TNM stage and age, according to national guidelines.
There were no significant difference in frequency of patients
receiving adjuvant chemotherapy between patients with mu-
tation (28%) and wild-type EGFR gene (26%).
Mutations
We identified EGFR mutations in a total of 18 of the
240 tumors (7.5%) (Table 2). Sixteen of the mutations were
detected among the 141 adenocarcinomas (11%) and 2
among the 63 squamous cell carcinomas (3%). The distribu-
tion of tumor stage was similar in the mutated and the
wild-type tumors. Median age in mutation-positive patients
was 66.5 years in females and 68.5 years in men.
We found mutations in eight of the never-smoking
patients (53%), eight of previous smokers (10%), and two of
the current smoking patients (1.4%) (Table 1). Fourteen of
the mutations (78%) were identified in female patients.
Among patients with wild-type EGFR gene, the median
tobacco consumption was 29 pack-years, while median pack-
years among mutated were 1.3. Five mutation-positive pa-
tients had smoked more than 20 pack-years. Females had
significantly higher mutation frequency regardless of smok-
ing history (p  0.0001). We identified one L861Q mutation
and one G719X mutation, both in heavy smokers, and one of
the L858R mutations was also detected in a heavy smoker.
One hundred seven of the 240 samples were also
analyzed by dHPLC combined with sequencing. dHPLC
TABLE 1. Characteristics of the Patients in This Cohort
Total Mutated p
Gender 0.008
Female 116 14
Male 124 4
Total 240 18
T stage NS
T1 81 6
T2 129 11
T3 17 0
T4 13 1
N stage NS
N0 175 11
N1 44 5
N2 21 2
Histology 0.017
Adenocarcinoma 141 16
Squamous cell carcinoma 63 2
Large cell carcinoma 23 0
Carcinoid 11 0
Adenosquamous 1 0
SCLC 1 0
p Stage NS
I 141 10
II 44 5
III 34 3
IV 3 0
Smoking 0.000
Current smoker 142 2
Former smoker 83 8
Never smoker 15 8
SCLC, small cell lung cancer; NS, not significant.
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failed to detect three mutations identified by the TheraScreen
Mutation Kit but identified a second mutation in one of the
samples (Table 2). EGFR protein expression was evaluated
by immunohistochemistry in 119 samples. We found no
significant correlation between protein levels and mutation
status (data not shown).
Exon 19 and Exon 21 Mutations
Fourteen of the 18 mutations were exon 19 deletions
or exon 21 point mutations. There was no significant
association between type of mutation and clinicopatholog-
ical characteristics (histology, p stage, T status, N status),
pack-years, or sex.
FIGURE 1. Difference in progres-
sion-free survival between patients
with an epidermal growth factor
receptor (EGFR) mutation versus
wild-type.
TABLE 2. Mutations Identified by the TheraScreen Mutation Kit and by dHPLC and Sequencing
Sample
Number
Mutation
TheraScreen dHPLC  Sequencing Gender Age (yr) Pack-Years Histology
T48 L858R Leu858Arg; ex21 F 75 0 AC
T59 L858R Leu858Arg; ex21 F 76 0 AC
T62 Deletion c.2240_2257del18; p.Leu747_Pro753delinSer; ex19 F 66 0 AC
T73 Deletion c.2235_2249del15; p.Glu746_Ala750del; ex19 F 56 10 AC
T97 Insertions Neg F 63 33 SCC
T104 Insertions 9BP insertion; ex20 F 75 5 AC
T107 Insertions c.2297_2235_dup9; p.Ala767_Val 769dup; ex20 F 70 0 BAC
T148 L858R Leu858Arg; ex21 M 71 0 AC
T169 L858R Not done M 81 24.5 AC
T175 Deletion c.2235_2249del15; p.Glu746_Ala750del; ex19 M 65 1.3 AC
T189 Deletion c.2240_2257del18; p.Leu747_Pro753delinSer; ex19 F 51 9 SCC
T194 Deletion c.2240_2257del18; p.Leu747_Pro753delinSer; ex19 F 70 0 AC
T195 Deletion Neg M 66 24.7 AC
T208 Deletion c.2236_2250del15; p.Glu746_Ala750del; ex19 F 65 0 BAC
T231 Deletion c.2235_2249del15; p.Glu746_Ala750del; ex19 F 73 0 AC
T249 G719X c.2126A  C; p.Glu709Ala; ex18, c.2155G  T;
p.Gly719Cys; ex18, -2 mutations
F 62 30 AC
T261 L858R Leu858Arg; ex21 F 48 2.5 AC
T266 L86IQ Neg F 67 39 AC
AC, adenocarcinoma; SCC, squamous cell carcinoma; BAC, bronchoalveolar carcinoma.
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Follow-Up
One of the mutation-positive patients have relapsed,
while 40 among the 222 patients (16%) with a wild-type
EGFR gene have relapsed, both at a median follow-up time of
18.2 months (p  0.174) (Figure 1).
DISCUSSION
Various estimates of the frequency of activating EGFR
mutations in lung cancer populations have been reported;
most studies are done in Asian patients or in selected groups
of patients. In our study, lung cancer patients scheduled for
surgery were screened for activating EGFR mutations using
two different screening methods. We found a mutation fre-
quency of 7.5%, which is lower than previously reported.
Studies on unselected Asian patients have reported frequen-
cies around 40%,8 whereas Rosell et al.5 found a mutation
frequency of 16% in a Spanish population. The last study was
not unselected, and the frequency among the current or
former smoking patients in that cohort was 5.8%, which is
close to our findings. A Russian study identified mutations in
20% of adenocarcinomas, as compared with 11% among the
adenocarcinomas in our cohort.9
We found mutations in 2 of 63 patients (3%) with
squamous cell carcinomas. Both were diagnosed based on
CK5/6 positivity in addition to unequivocal morphology, as
decided by two independent pathologists. The reported fre-
quency of activating mutations in squamous cell histology
has been very low, perhaps reflecting the low incidence of
this histological subtype in Asian patients, as well as biased
screening routines in many centers, where only nonsquamous
histologies have been tested.
Our cohort consisted of 94% smokers or former smok-
ers. However, 44% of the patients having activating muta-
tions were never-smokers, and 53% of the never-smokers
were diagnosed with mutations, reflecting and underscoring
other reports showing the propensity of this mutation in
never-smokers. Only 2 of 142 current smokers (1.4%) carried
the mutation, whereas 10% of the former smokers had a
mutation. This may point to subgroups that should be tested
for a mutation. However, several of the current or former
smokers with mutations had smoked a substantial number of
pack-years.
Although our cohort is relatively small and has a
relatively short follow-up time, it is interesting to observe that
only one of the 18 patients with mutations have relapsed
(median observation time  18.2 months), whereas approx-
imately 18% of patients with wild-type EGFR had relapsed
within 2 years after surgery. None of the patients in our
cohort have been treated with tyrosine kinase inhibitors,
whereas patients in stage II to III have been offered standard
adjuvant chemotherapy. Stage, gender, and age distributions
were not significantly different between mutation-positive
versus mutation-negative. This may indicate that a mutation
per se has prognostic impact, in line with other studies.
The DxS kit is designed to pick 28 different mutations
within the kinase domain of EGFR. To test if there were other
mutations not detected using this kit, we also performed
dHPLC followed by sequencing, which may detect any mu-
tation within the sequenced domains. One additional muta-
tion in exon 18 was found. This sample contained two
mutations in exon 18, of which only one was detected by the
DxS kit. Three of the tumors detected as positive using the
DxS kit were not detected by sequencing, possibly due to
lower sensitivity of sequencing compared with the DxS kit.
In conclusion, we have found a low but clinically
relevant frequency of EGFR mutations in a population of
Northern European lung cancer patients. Even though the
frequency is higher in never-smokers, females, and adeno-
carcinomas, we find that the mutation is relevant also in
smokers and squamous cell carcinomas. Activating mutations
in EGFR seem to be related to a better prognosis and are
easily detected using the DxS kit.
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